Multiple myeloma(MM),a malignancy of clonalplasma cells,is characterized by proliferation andaccumulation of abnormal plasmacytes in bone marrow,monoclonal immunoglobulin or its fragment secretions(M-protein)in serum or urine and concomitant extensiveosteolytic lesions and/or osteoporosis,anemia,infectionor renal dysfunction.The incidence rate of MM hasgradually increased in recent years.Traditionalchemotherapy results in median survival duration of nomore than three years,a 25% five-year survival rate and aten-year survival rate of less than 5%.It remains anincurable disease and particularly threatens the health ofmiddle-aged and old-aged people.With the recent studieson biologic characteristics,intracellular signaltransduction pathways and bone marrow micro-environment and their interactions,there emerged newdrugs that have resulted in progress in the treatment ofMM,which are sununarized as follows. Multiple myeloma (MM), a malignancy of clonalplasma cells, is characterized by proliferation and accumulation of abnormal plasmacytes in bone marrow, monoclonal immunoglobulin or its fragment secretions (M-protein) in serum or urine and concomitant extensiveosteolytic lesions and / or osteoporosis, anemia, infectionor renal dysfunction.The incidence rate of MM hasgradually increased in recent years.Traditionalchemotherapy results in median survival duration of nomore than three years, a 25% five-year survival rate and aten-year survival rate of less than 5% .It remains anincurable disease and particularly threatens the health of mid-aged and old-aged people. W. the recent studies on biologic characteristics, intracellular signal transduction pathways and bone marrow micro-environment and their interactions, there emerging new drugs that that resulted in progress in the treatment of MM, which are sununarized as follows.